SCHEMBL6090652

SCHEMBL6090652

O=C1NC(=S)SC1=Cc1ccc(-c2ccccc2Br)o1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 5/20 0.74
INSR P06213 3/20 0.74
PTP4A3 O75365 1/20 0.69
PIK3CG P48736 9/20 0.66
PIK3CA P42336 2/20 0.58
PIK3CB P42338 1/20 0.58
GSK3B P49841 2/20 0.56
GSK3A P49840 1/20 0.56
PIM1 P11309 1/20 0.54
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
HPGD P15428 1/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
RECQL P46063 1/20 0.54
KMT2A Q03164 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090645 1.00 IGF1R (0.74) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL29910211 1.00 IGF1R (0.74) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL623776 0.85 IGF1R (1.00) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL622800 0.85 PIK3CG (0.80) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL623774 0.85 IGF1R (1.00) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL623775 0.85 IGF1R (1.00) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL622799 0.85 PIK3CG (0.80) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL622801 0.85 PIK3CG (0.80) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL3907984 0.83 IGF1R (0.81) IGF1RINSRPTP4A3PIK3CGPIK3CA
SCHEMBL3907981 0.83 IGF1R (0.81) IGF1RINSRPTP4A3PIK3CGPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 IGF1R 1698/4885INSR 2538/4885PTP4A3 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.